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However, 36 (8%) did not satisfy the inclusion criteria. Specifically, 12 subjects did not have stage IIIB or IV disease, 9 had insufficient documentation, and the remainder did not meet study requirements. 202 patients (median age 61 years, range: 32 -83 years; 67% male, 79% white) were included in the vinorelbine+cisplatin group and 206 patients (median age 62 years, range: 26 -80 years; 70% male, 79% white) were included in the paclitaxel+carboplatin group.
Study design
The study was an open, randomised controlled trial carried out in 108 sites of the SWOG. The method of randomisation was not reported. Patients were followed for 24 months from the moment of randomisation and were then assessed through a questionnaire (Functional Assessment of Cancer Therapy-Lung Questionnaire) administered at the time of randomisation, and at 3 and 6 months after randomisation. No loss to follow-up was reported.
Analysis of effectiveness
The clinical analysis was conducted on an intention to treat basis. The primary health outcomes were survival rates at 1 and 2 years, median survival, and quality of life values. The instruments used to assess these data were not reported. Statistical analyses showing the comparability of the groups in terms of demographics and clinical characteristics were not reported, but the two groups appear to have been quite similar.
Effectiveness results
Survival rates at years 1 and 2 were 36% and 16% in the vinorelbine+cisplatin group and 38% and 15% in the paclitaxel+carboplatin group.
Median survival was 8 months in both groups.
Quality of life values were not reported.
Overall, there was no statistically significant difference between the groups with respect to any of the health outcomes considered.
Clinical conclusions
The two drug therapies appeared to be equally effective in terms of survival and quality of life.
Measure of benefits used in the economic analysis
Since no statistically significant difference was found between the study groups in terms of health outcomes, no summary benefit measure was used and, as such, a cost-minimisation analysis was conducted.
Direct costs
Costs occurring after year 1 were discounted at 3%. Unit costs were not reported. Average quantities of resources were reported only for hospital and outpatient services. The cost/resource boundary adopted in the study reflected the perspective of the analysis. The health services costs included in the analysis were as follows: medical procedures, blood products, supportive medication, protocol chemotherapy (delivery and drug), non-protocol therapy, and medical care days/visits. Costs related to the treatment of side-effects of the therapies were also included and were derived from a special form aimed at capturing resource use. The estimation of costs was based on data derived from nationally representative databases and Medicare reimbursement rates. Quantities of resources used were gathered from April 1996 to January 1998. 1998 prices were used through the medical care component of the consumer price index.
Statistical analysis of costs
Costs were mainly treated deterministically, but some statistical analyses were conducted to allow comparisons among the cost items included in the analysis. comparability of study groups. Power calculations were not reported, but the sample size was quite large. The study population was somewhat heterogeneous coming, as it did, from different settings, therefore the external validity of the effectiveness analysis was also high. The authors noted that patient monitoring was probably more intense than in a typical clinical practice, because the study was a controlled trial. Information on second-and third-line chemotherapies was not collected.
Validity of estimate of measure of benefit
No summary benefit measure was used and costs and benefits were not combined because a cost-minimisation analysis was conducted, since no statistical difference was found between the groups in terms of clinical outcomes.
Validity of estimate of costs
All categories of costs relevant to the perspective adopted appear to have been included in the analysis. The authors highlighted the fact that medical resource use was tracked well beyond the initial protocol treatment period using special forms in each centre in which the study was carried out. Costs were discounted and quantities of resources used were reported for some items. However, unit costs were not reported and cost estimates appeared to be quite specific to the study setting, and therefore may not be valid for different providers in different settings. Statistical analyses on quantities of resources used were not reported.
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